Jaisim Shah Email Address

Chief Executive Officer Scilex Holding

Focusing on the development of oncologic agents for the treatment for cancers

CEO, Board Director growing shareholder value at life science companies. Successful accomplishments at Bristol-Myers, Roche, PDL, Sorrento, Elevation, Semnur/Scintilla Pharmaceuticals.Over 25 year industry success in product development & commercializing therapies at Roche, BMS, PDL. Managed late stage product development for Rituxan, Pegasys, Abilify pre-launch teams, each over $2 billion sales. Have successfully led product development plans and operational teams. Broad Expertise in product development, commercialization of compounds in variety of indications: Oncology, Respiratory, Immunology, Infectious Disease, Virology, CNS, Autoimmune, Inflammation, CV, Pain. Milestones: Created and implemented successful alliances/M&A transactions - $1.2 billion collaboration PDL/BMS (Top 5 Antibody Mega Deals, BioCentury 2009)- $800 million PDL-Biogen Idec collaboration- $430 million Elevation Pharma to Sunovion (Top 10 Acquisitions of VC companies, WSJ 2012)- $200 million sale of IV Busulfex to Otsuka - $300 million multiple collaborations with Roche- Sorrento acquisition of Igdrasol/CynviloqGlobal deal-maker with proven partnering and negotiation skills, strong track record of closing licensing and strategic partnerships with cumulative deal values of >$1 billion. Held senior leadership positions at global and development stage companies, VP of Franchise Management at Bristol-Myers Squibb, Chief Business Officer at PDL and Elevation, CEO at Semnur, Board Director at Sorrento. Honored with numerous company awards, including BMS President’s Award. Expertise in M&A and Collaborations with Bristol-Myers Squibb, total transaction value of more than $1 billion, as well as a global transaction with Biogen Idec, with a total transaction value of $800 million, and multiple collaborations with Roche with transaction values of more than $350 million. Sale of Elevation to Dainippon Sumitomo for $430m.